Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 3/20 | 0.43 |
| ▸ | DRD2 | P14416 | 3/20 | 0.43 |
| ▸ | HTR7 | P34969 | 3/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 5/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 10/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4306062 | 0.92 | HTR2A (0.42) | HTR1ADRD2HTR7ADRA1DADRA1A | |
| SCHEMBL4306503 | 0.89 | F10 (0.42) | HTR1ADRD2HTR7ADRA1DADRA1A | |
| SCHEMBL4302294 | 0.85 | MAPT (0.42) | HTR1ADRD2HTR7ADRA1BF10 | |
| SCHEMBL5466430 | 0.85 | HTR1A (0.47) | HTR1ADRD2HTR7ADRA1DADRA1A | |
| SCHEMBL4306493 | 0.84 | F10 (0.43) | HTR1ADRD2HTR7ADRA1DADRA1A | |
| SCHEMBL4310791 | 0.84 | DRD2 (0.41) | HTR1ADRD2HTR7F10 | |
| SCHEMBL4307569 | 0.84 | MAPT (0.43) | DRD2HTR7ADRA1DADRA1AF10 | |
| SCHEMBL4309292 | 0.84 | F10 (0.39) | HTR1ADRD2HTR7F10 | |
| SCHEMBL4310904 | 0.83 | L3MBTL1 (0.45) | ADRA1DADRA1AADRA1BTP53 | |
| SCHEMBL4302265 | 0.83 | F10 (0.44) | HTR1ADRD2HTR7F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482472-B2 | Substituted isoindoles and their use | BAYER HEALTHCARE AG (DE) | 2009-01-27 | — | — | US | disclosed |
| US-20080039446-A1 | Substituted isoindoles and their use | BAYER HEALTHCARE AG (DE) | 2008-02-14 | — | — | US | disclosed |
| US-7189738-B2 | Substituted isoindoles and their use thereof | BAYER HEALTHCARE AG (DE) | 2007-03-13 | — | — | US | disclosed |
| EP-1414817-B1 | substituted isoindoles and the use thereof | BAYER HEALTHCARE AG (DE) | 2005-04-06 | — | — | EP | disclosed |
| US-20040215019-A1 | Substituted isoindoles and the e use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039446-A1 | Substituted isoindoles and their use | F2, F12, TFPI2 | HTR1A 527/4885DRD2 1154/4885HTR7 191/4885 |
| US-20040215019-A1 | Substituted isoindoles and the e use thereof | F2, F12, F5 | HTR1A 580/4885DRD2 1163/4885HTR7 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.